Capdevila J, Rojo F, Gonzalez-Martin A, et al. Molecular profiling for clinical decision making in advanced cancer: a clinical appraisal. Journal of Cancer Research and Treatment. 2017;5(3):77-85.

Findings from a new clinical appraisal of molecular profiling for clinical decision making in advanced cancer

A new publication written by an experienced group of Spanish oncologists and pathologists,1 has provided a clinical appraisal of molecular profiling for clinical decision making in advanced cancer.

In this paper, the authors looked at three commercially available tumour profiling platforms in Spain – Caris Molecular Intelligence® (CMI), FoundationOne® and OncoDEEP™. An extensive literature review and collection of information from websites of each platform was completed and discussed between the authors in a review meeting.

In the paper, the authors gave an overview of the treatment associations tested for all tumours and highlighted the advantages of CMI, which had the most comprehensive coverage of chemotherapy and hormone therapies. The authors also compared the external quality certifications and accreditations held by each platform, of which Caris Molecular Intelligence® held the highest levels of certification.

The paper also gave an overview of the demonstrated clinical utility of the three platforms and showed the impact and percentage of patients treated. There was a decision impact of 88% for CMI compared to 27% for FoundationOne® and based on the studies presented, 75% of CMI-profiled patients were treated compared to 24% of those profiled in FoundationOne® studies. In addition, the authors showed that 40% of CMI-treated patients have clinical benefit compared to 27% in Foundation’s studies, and that no data has yet to be presented for OncoDEEP™.

The authors concluded that their review supports that Caris Molecular Intelligence, “offers the most complete multiplatform profile with which favourable clinical outcome data were produced. These clinical outcome data clearly show that with the right approach to clinical use, the broader practice is well justified as the clinical benefit has been demonstrated.”1

Reference

  1. Capdevila J, Rojo F, Gonzalez-Martin A, et al. Molecular profiling for clinical decision making in advanced cancer: a clinical appraisal. Journal of Cancer Research and Treatment. 2017; 5(3): 77-85. [Full text]
Print Friendly, PDF & Email
Created: - Modified: